• Please log in or register to access this feature.

Viral Hepatitis

You have full text access to this OnlineOpen article

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B†

  1. Karsten Wursthorn1,‡,
  2. Marc Lutgehetmann1,‡,
  3. Maura Dandri1,
  4. Tassilo Volz1,
  5. Peter Buggisch1,†,
  6. Bernhard Zollner2,†,
  7. Thomas Longerich3,
  8. Peter Schirmacher3,
  9. Frauke Metzler1,
  10. Myrga Zankel4,
  11. Conrad Fischer5,
  12. Graeme Currie5,
  13. Carol Brosgart5,
  14. Joerg Petersen1,§,†,*

Article first published online: 29 AUG 2006

DOI: 10.1002/hep.21282

Issue

Hepatology

Hepatology

Volume 44, Issue 3, pages 675–684, September 2006

Additional Information

How to Cite

Wursthorn, K., Lutgehetmann, M., Dandri, M., Volz, T., Buggisch, P., Zollner, B., Longerich, T., Schirmacher, P., Metzler, F., Zankel, M., Fischer, C., Currie, G., Brosgart, C. and Petersen, J. (2006), Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology, 44: 675–684. doi: 10.1002/hep.21282

Author Information

  1. 1

    Department of Medicine, University Hospital Hamburg–Eppendorf, Hamburg, Germany

  2. 2

    Department of Microbiology, University Hospital Hamburg–Eppendorf, Hamburg, Germany

  3. 3

    Institute of Pathology, University of Heidelberg, Heidelberg, Germany

  4. 4

    Essex Pharma GmbH, Munich, Germany

  5. 5

    Gilead Sciences Inc, Foster City, CA

  1. †

    Potential conflict of interest: Dr. Zollner received travel grants from Gilead. Dr. Petersen received grants from Gilead. Dr. Buggisch is on the Speakers' Bureau for and received grants from Schering-Plough. He also received grants from Gilead.

  2. ‡

    K. Wursthorn and M. Lutgehetmann contributed equally to this work.

  3. §

    fax: (49) 40-42803-8065

*Medizinische Klinik und Poliklinik I, Zentrum für Innere Medizin, Universitätsklinikum Hamburg—Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany

  1. †

    Potential conflict of interest: Dr. Zollner received travel grants from Gilead. Dr. Petersen received grants from Gilead. Dr. Buggisch is on the Speakers' Bureau for and received grants from Schering-Plough. He also received grants from Gilead.

  2. ‡

    K. Wursthorn and M. Lutgehetmann contributed equally to this work.

  3. §

    fax: (49) 40-42803-8065

Publication History

  1. Issue published online: 29 AUG 2006
  2. Article first published online: 29 AUG 2006
  3. Manuscript Accepted: 25 MAY 2006
  4. Manuscript Received: 11 MAR 2006

Funded by

  • Deutsche Forschungsgemeinschaft. Grant Number: Pe/608 2-4
  • Virgil (European Union Network of Excellence)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (493K)

References

  • 1
    Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995; 69: 3350–3357.
  • 2
    Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 1990; 175: 255–261.
  • 3
    Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302–308.
  • 4
    Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997; 71: 9392–9399.
  • 5
    Dandri M, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. HEPATOLOGY 2000; 32: 139–146.
    Direct Link:
  • 6
    Jacquard AC, Nassal M, Pichoud C, Ren S, Schultz U, Guerret S, et al. Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 2004; 48: 2683–2692.
  • 7
    Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001; 75: 311–322.
  • 8
    Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750–1758.
  • 9
    Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65–91.
  • 10
    Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari V. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825–829.
  • 11
    Wieland SF, Spangenberg HC, Thimme R, Purcell RH, Chisari FV. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A 2004; 101: 2129–2134.
  • 12
    Guo JT, Zhou H, Liu C, Aldrich C, Saputelli J, Whitaker T, et al. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol 2000; 74: 1495–1505.
  • 13
    Summers J, Jilbert AR, Yang W, Aldrich CE, Saputelli J, Litwin S, et al. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci U S A 2003; 100: 11652–11659.
  • 14
    Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104–1108.
  • 15
    Dandri M, Burda MR, Zuckerman DM, Wursthorn K, Matschl U, Pollok JM, et al. Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. J Hepatol 2005; 42: 54–60.
  • 16
    Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. HEPATOLOGY 2001; 33: 1527–1532.
    Direct Link:
  • 17
    Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085–1089.
  • 18
    Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890–1897.
  • 19
    Gerlich WH, Wend U, Glebe D. Quantitative assay of hepatitis B surface antigen in serum or plasma using laurell electrophoresis. Methods Mol Med 2004; 95: 57–63.
  • 20
    Loeb KR, Jerome KR, Goddard J, Huang M, Cent A, Corey A. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. HEPATOLOGY 2000; 32: 626–629.
    Direct Link:
  • 21
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–699.
  • 22
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994; 19: 1513–1520.
    Direct Link:
  • 23
    Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. HEPATOLOGY 1994; 20: 349–355.
    Direct Link:
  • 24
    Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263–270.
  • 25
    Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000; 118: S83–103.
  • 26
    Zoulim F. Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. J Antimicrob Chemother 2005; 55: 608–611.
  • 27
    Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. HEPATOLOGY 2003; 37: 1309–1319.
    Direct Link:
  • 28
    Le Guerhier F, Pichoud C, Guerret S, Chevallier M, Jamard C, Hantz O, et al. Characterization of the antiviral effect of 2′,3′-dideoxy-2′,3′-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 2000; 44: 111–122.
  • 29
    Nicoll AJ, Colledge DL, Toole JJ, Angus PW, Smallwood RA, Locarinini SA. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Antimicrob Agents Chemother 1998; 42: 3130–3135.
  • 30
    Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68–76.
  • 31
    Zhou T, Guo JT, Nunes FA, Molnar-Kimber KL, Wilson JM, Aldrich CE, et al. Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections. J Virol 2000; 74: 11754–11763.
  • 32
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682–2695.
  • 33
    Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422–1427.
  • 34
    Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562–568.
View Full Article (HTML) Get PDF (493K)